Verrica Pharmaceuticals
2013
FOUNDED
PUBLIC
STATUS
11-20
EMPLOYEES
VRCA
STOCK SYMBOL
$15.88
SHARE PRICE
(As of Thursday Closing)
Description
Verrica Pharmaceuticals Inc a clinical-stage biopharmaceutical company. The company is primarily focused on identifying, developing and commercializing pharmaceutical products for the treatment of skin diseases with unmet needs. Its pipeline product includes NCT03377803, and NCT03377790.
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
NAS
Primary Office
- Durham, NC
- United States
+1 (610) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Verrica Pharmaceuticals’s full profile, request a free trial.
Verrica Pharmaceuticals Stock Performance
| 52 wk Range | Market Cap | Prev. Close | EPS | Average Volume | Shares |
|---|---|---|---|---|---|
| $6.84 - $18.67 | $409M | $15.50 | -$1.13 | 74.4K | 25.8M |
Verrica Pharmaceuticals Financials Summary
|
In Thousands,
USD |
TTM
30-Sep-2019
|
FY 2018
31-Dec-2018
|
FY 2017
31-Dec-2017
|
FY 2016
31-Dec-2016
|
|---|---|---|---|---|
| Enterprise Value | 301,436 | 112,450 | ||
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (30,107) | (21,859) | (4,457) | (1,913) |
| Net Income | (28,148) | (20,648) | (4,459) | (1,913) |
| Total Assets | 76,074 | 91,906 | 9,083 | 544 |
| Total Debt | 218 | 0 | 0 | 0 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Verrica Pharmaceuticals Valuation and Funding
| Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
|---|
This information is reserved for PitchBook Platform users. To explore Verrica Pharmaceuticals‘s full profile, request access.
Request full access to PitchBookVerrica Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
This information is reserved for PitchBook Platform users. To explore Verrica Pharmaceuticals‘s full profile, request access.
Request full access to PitchBookVerrica Pharmaceuticals Competitors (6)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Aclaris Therapeutics | Formerly VC-backed | Wayne, PA | 000 | 00000 | 00000000000 | 00000 |
| 0000000 0000000000 | Formerly VC-backed | Newark, CA | 000 | 00000 | 00000000 | 00000 |
| 00000000 000000000 | Venture Capital-Backed | San Diego, CA | 0000000000 | |||
| 000000 | Formerly PE-Backed | Irvine, CA | 000 | 00000 | 00000000 | 00000 |
| 0000 0000000000000 | Formerly PE-Backed | West Chester, PA | 000000&0 |
Verrica Pharmaceuticals Investors
| Investor Name | Investor Type | Holding | Participating Rounds | Investor Since | Board Seat | Contact Info |
|---|
This information is reserved for PitchBook Platform users. To explore Verrica Pharmaceuticals‘s full profile, request access.
Request full access to PitchBookVerrica Pharmaceuticals Executive Team (5)
| Name | Title | Board Seat |
Contact Info |
|---|---|---|---|
| Ted White | Chief Executive Officer & Board Member | ||
| Matthew Davidson Ph.D | Founder, Chief Scientific Officer & Board Member |
3 Former Executives
You’re viewing 2 of 5 executives. Get the full list »Verrica Pharmaceuticals Board Members (6)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Glenn Oclassen | Verrica Pharmaceuticals | Board Member | 000 0000 | |
| Matthew Davidson Ph.D | Verrica Pharmaceuticals | Founder, Chief Scientific Officer & Board Member | 000 0000 | |
| Paul Manning | PBM Capital Group | Chairman & Board Member | 000 0000 | |
| Sean Stalfort | Verrica Pharmaceuticals | Board Member | 000 0000 | |
| Ted White | Verrica Pharmaceuticals | Chief Executive Officer & Board Member | 000 0000 |
1 Former Board Member
You’re viewing 5 of 6 board members. Get the full list »